Online Business

UTI MF to launch mobile platform by Jan-end

With a view to attract more investors, leading fund house, UTI Mutual Funds today said it plans to launch mobile transaction platform by January-end, a top official said. - Persistent sets up CoE for Android platform applications - UTI MF revises exit load - MFs on a volcano; using short-term funds for long-term lending - UTI MF to use SMS, innovative channels for marketing - Debt funds drive record growth in MF assets "We would launch this platform for investors by January-end, which would enable them to buy, sell and switch MF products through their mobile," UTI MF Chief Marketing Officer Jaideep Bhattacharya told PTI. Recently, both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) had launched mutual fund trading platforms. The BSE is also gearing up to launch its mobile mutual fund platform for brokers. The exchange is likely to come out with an announcement shortly. UTI MF, which is the first fund that joined the NSE MF platform, expects a significant pick up in trades through the new exchange infrastructure, Bhattacharya said. "It (the MF transactions through exchanges) is picking up. This provides an easier option to the investor to buy a MF product," he said. The number of accounts with UTI AMC has crossed the one-crore mark indicating the faith reposed by investors in the fund, which currently offers 100 schemes, Bhattacharya said. The fund plans to increase focus on retailing its products to customers in rural, urban and semi-urban areas, Bhattacharya said.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

News of the day
Govt rejigs accounts to spend Rs 25,725 cr
To dole out Rs 3,000 cr to fertiliser companies; Rs 800 cr to AI
Popular Articles

Camera indica
A hundred and fifty years after photographer James Waterhouse charmed Nawab Sikander Begum of Bhopal to sit for him, an illustrated tome on the encounter, and other Indian trysts, enthralls Gargi Gupta.

Sun Pharma, Forest settle US suit on Lexapro
Sun Pharmaceutical Industries and its subsidiary, Caraco Pharmaceutical Laboratories, have reached a settlement agreement with drugmaker Forest Laboratories and licensing partner H Lundbeck AS, over a pending patent infringement dispute over Forest’s blockbuster antidepressant, Lexapro.